Compared with the albumin and liposomal formulations, which have the average size of around 100 nm, ADC is in the optimal size (≈5–15 nm) that is capable of escaping from reticularendothelial system (RES) uptake, resulting in a prolonged therapeutic window.[34, 35, 36, 37] The blood half‐life is ≈4.5 days for ADCs, in comparison with 20–30 h of albumin and liposomal formulations.[38, 39, 40] The prolonged circulation time as well as the conserved complex with bioactivities leads to more effective accumulation in the tumor site and less toxicity to the normal tissues. This evidence concerns the gene ALB and neoplasm.